On Monday, the Drugs Controller General of India (DCGI) granted approval for the emergency usage of Corbevax, a COVID-19 vaccine developed by Hyderabad-based Biological E, for children between 12 to 18 years of age.
The approval was given after positive interim results of the ongoing phase II and III clinical trials.
"We are pleased with this significant development which helps extend the reach of our vaccine to the age group of 12 to 18 years in our country," Mahima Dalta, managing director of Biological E was quoted.
Corbevax is administered through intramuscular route with two doses scheduled 28 days apart.
It will be the third vaccine after ZyCoV-D and Covaxin which has received approval for those below 18 years of age.
With more than 7 lakh doses administered on Monday, India' cumulative COVID-19 vaccination coverage crossed 175.46 crore mark.
0 Comments